|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.31 USD | +2.34% |
|
+6.24% | -30.32% |
| May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
| May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
IO Biotech, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 71.46 million compared to USD 67.88 million a year ago. Basic loss per share from continuing operations was USD 2.48 compared to USD 17.3 a year ago.
Diluted loss per share from continuing operations was USD 2.48 compared to USD 17.3 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -30.32% | 86.3M | |
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
IO BIOTECH, INC. 
